Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinCharles J. Fisher, Ernest Benjamin, Jan M. Agosti et al.|New England Journal of Medicine|1996Cited by 1.3k
Confirmatory interleukin-1 receptor antagonist trial in severe sepsisSteven M. Opal, Michael G. Seneff, Janice L. Lookabaugh et al.|Critical Care Medicine|1997Cited by 863
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCharles J. Fisher, Michael A. Catalano, Gus J. Slotman et al.|Critical Care Medicine|1994Cited by 490
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsisCharles J. Fisher, Jerald Sadoff, Steven M. Opal et al.|Critical Care Medicine|1993Cited by 431